NCT02378701View on ClinicalTrials.gov

Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease

CompletedOBSERVATIONAL
Enrollment

102

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

July 18, 2022

Study Completion Date

July 18, 2022

Conditions
Leukemia
Interventions
BEHAVIORAL

QUALMS-1 Questionnaire

Participants complete the QUALMS-1 during first treatment visit, and after 4th cycle of treatment or when treatment stops.

BEHAVIORAL

FACT-An Questionnaire

Participants complete the FACT-An during first treatment visit, and after 4th cycle of treatment or when treatment stops.

Trial Locations (6)

10065

Weill Medical College of Cornell University, New York

21218

The Johns Hopkins University, Baltimore

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

44195

Cleveland Clinic Foundation, Cleveland

77030

University of Texas MD Anderson Cancer Center, Houston

02215

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

MDS Clinical Research Consortium

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT02378701 - Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease | Biotech Hunter | Biotech Hunter